Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tvardi Therapeutics Inc. faces a potential business risk due to its amended and restated certificate of incorporation, which mandates that the Court of Chancery of the State of Delaware is the exclusive forum for most disputes between the company and its stockholders. This provision could limit stockholders’ ability to seek a favorable judicial forum and increase the cost of bringing claims against Tvardi, potentially discouraging lawsuits. However, if a court finds this provision unenforceable, Tvardi may incur significant additional costs litigating in other jurisdictions, which could adversely affect its business operations and financial condition. The uncertainty surrounding the enforceability of these exclusive forum provisions poses a risk to Tvardi’s legal strategy and financial stability.
The average TVRD stock price target is $58.83, implying 145.13% upside potential.
To learn more about Tvardi Therapeutics Inc.’s risk factors, click here.